Anakinra | Canakinumab | Rilonacept | |
Target | IL-1alpha, IL-1beta | IL-1beta | IL-1alpha, IL-1beta* |
Mechanism of action | IL-1ra | Anti-IL-1beta | IL-1 "trap" fusion protein |
IgG isotype | N/A | IgG1, kappa | IgG1 (heavy chains only) |
Half-life | 4 to 6 hours | 26 days | 7 days |
Administration | Subcutaneous (IV) | Subcutaneous¶ | Subcutaneous |
Administration interval | Daily | Every 1 to 2 months | Weekly |
Renal dose adjustment | Yes | No | No |
Antiinflammatory potency | +++ | +++ | ++ |
FDA-approved indications |
|
|
|
EMA-approved indications |
|
|
|
Common off-label uses (in addition to FDA- and EMA-approved uses) |
| ||
Select adverse effects |
|
|
|
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟